BTK inhibitors and methods for their identification and use

Details BTK inhibitors and methods for their identification and use BTK inhibitors and methods for their identification and use

2000-10-16

2001-09-25

O'Sullivan, Peter (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S238500, C514S331000, C514S428000, C514S548000, C544S163000, C546S230000, C548S567000, C558S392000, C560S250000

Reexamination Certificate

active

06294575

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to inhibitors of the family tyrosine kinase, and particularly, inhibitors of Bruton's Tyrosine Kinase (BTK).
BACKGROUND OF THE INVENTION
Apoptosis is a common mode of eukaryotic cell death which is triggered by an inducible cascade of biochemical events leading to activation of endonucleases that cleave the nuclear DNA into oligonucleosome-length fragments. Several of the biochemical events that contribute to apoptotic cell death as well as both positive and negative regulators of apoptosis have recently been identified (Whyllie A., et al. (1980)
Int. Rev. Cytol
. 68, 251-305; Steller H., (1995)
Science
267, 1445-1449; Fraser, A., Evan, G. (1996)
Cell
85, 781-784; and Korsmeyer, S. J. (1995).
Trends Genet
. 11, 101-105). Apoptosis plays a pivotal role in the development and maintenance of a functional immune system by ensuring the timely self-destruction of autoreactive immature and mature lymphocytes as well as any emerging target neoplastic cells by cytotoxic T cells.
In addition to the beneficial effects associated with apoptosis, inappropriate apoptosis contributes to the pathogenesis and drug resistance of human leukemias and lymphomas (Cohen. J. J., et al. (1992)
Annu. Rev. Immunol
. 10, 267-293; Linette, G. P., Korsmeyer, S. J. (1994)
Curr. Opin. Cell Biol
. 6, 809-815; and Thompson, C. B. (1995)
Science
367, 1456-1462). Thus, agents that are useful to modulate apoptosis are potentially useful as therapeutic agents for treating diseases in which inappropriate apoptosis is implicated. As a result, there is a considerable amount of ongoing research devoted to the identification of molecular regulators of apoptosis, and there is currently a need for novel agents (e.g. chemical or biological), and novel therapeutic methods, that are useful for modulating apoptosis. Such agents and methods may be useful for treating cancer (e.g. leukemias and lymphomas) or immune disorders in mammals. They may also be useful as pharmacolocical tools for use in in vitro or in vivo studies to enhance the understanding of the molecular basis of apoptosis (e.g. the pro-apoptotic versus the anti-apoptotic regulatory signal), as well as the pathogenesis of human lymphoid malignancies.
SUMMARY OF THE INVENTION
The inventino provides inhibitors of Tec family tyrosine kinases, and particularly of BTK. The inhibitors of the invention are useful in the treatment of pathologic conditions involving cells expressing Tec family tyrosine kinaes, such as T cells (Tec, Itk) and B cells (BTK).
The invention provides compounds of formula I:
where:
R
1
is (C
1
-C
3
)alkyl, (C
3
-C
6
)cycloalkyl, phenyl, or NR
a
R
b
;
R
2
is hydroxy, (C
1
-C
6
)alkoxy, (C
1
-C
6
)alkanoyloxy amino (C
2
-C
5
)alkoxy; hydroxy (C
2
-C
5
)alkoxy amino (C
2
-C
5
)alkanoxy; or hydroxy (C
2
-C
5
) alkanoxy;
R
3
is cyano or (C
1
-C
3
)alkanoyl;
R
4
is hydrogen, (C
1
-C
3
)alkyl; hydroxy (C
2
-C
5
)alkyl; or amino (C
2
-C
5
)alkyl;
R
5
is aryl, or heteroaryl;
R
a
and R
b
are each independently hydrogen, or (C
1
-C
3
)alkyl; or R
a
and R
b
together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino;
wherein any aryl, or heteroaryl of R
1
and R
5
is optionally substituted with one or more (e.g. 1, 2, or 3) substituents independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, (C
1
-C
3
)alkoxy, (C
1
-C
3
)alkyl, (C
1
-C
3
)alkanoyl, —S(O)
2
R
c
, or NR
a
R
b
; wherein R
c
is (C
1
-C
3
)alkyl, or aryl
or a pharmaceutically acceptable salt thereof;
provided that if R
5
is phenyl, the phenyl is substituted by —S(O)
2
R
c
, or is substituted by halo and at least one other substituent.
The invention also provides a compound of formula II:
where:
X is O, N, or S;
R
1
is H, alkyl, carboxyl,
preferably C
1
-C
3
alkyl or C
1
-C
3
carboxyl; and
R
2
is alkyl, preferably C
1
-C
6
alkyl.
The compounds of the invention are designed to fit a composite binding pocket model of the BTK domain, having a molecular volume of less than the volumne of the binding pocket (e.g., less than about 600 Å
3
) and preferably a volume that approaches ⅔ the volume of the pocket, e.g., approximately 400 Å
3
. Most preferably, the inhibitors of the invention are designed to fille the space of the binding pocket and to interact with residues of the pocket for enhanced binding.
The invention also provides a pharmaceutical composition comprising an agent that inhibits or prevents the action of Bruton's tyrosine kinase; and a pharmaceutically acceptable carrier.
The invention also provides a method to promote or induce apoptosis in a BTK expressing cell comprising contacting the cell with an agent that inhibits or prevents the action of BTK.
The invention also provides a method to treat a disease (pathologic condition) wherein BTK is implicated and inhibition of its action is desired comprising administering to a mammal in need of such treatment an effective amount of an agent that inhibits or prevents the action of BTK.
The invention also provides a method to lower the resistance of a BTK expressing cell to drug therapy comprising contacting the cell with an agent that inhibits or prevents the action of BTK.
The invention provides a BTK inhibitor for use in medical therapy (preferably for use in treating cancer or other BTK mediated diseases), as well as the use of a compound of formula I for the manufacture of a medicament for the treatment of a pathological condition or symptom in a mammal, such as a human, which is associated with BTK (e.g. cancer, such as a leukemia or a lymphoma).


REFERENCES:
patent: 5308865 (1994-05-01), Bartlett et al.
patent: 5489697 (1996-02-01), Boulanger et al.
patent: 5494911 (1996-02-01), Bartlett et al.
patent: 5700823 (1997-12-01), Hirth et al.
patent: 5747664 (1998-05-01), Schleyerbach et al.
patent: 5780592 (1998-07-01), Müllner et al.
patent: 25 55 685 (1977-06-01), None
patent: 0 537 742 A2 (1993-04-01), None
patent: 0 551 230 A1 (1993-07-01), None
patent: 0 652 214 A1 (1995-05-01), None
patent: WO 91/17748 (1991-11-01), None
patent: WO 94/14789 (1994-07-01), None
patent: WO 96/26934 (1996-09-01), None
patent: WO 96/31206 (1996-10-01), None
patent: WO 98/25608 (1998-06-01), None
Chemj. Abst. 96:34913 (1982).
Chem Abst. 86:105977 (1977).
Ahluwalia, V. et al., “Formation of 4-Ethylcoumarins from&bgr;-Diketones-Reaction Mechanism”,Indian Journal of Chemistry,vol. 15B, pp. 240-241 (1977).
Crombie, L. et al., “Synthesis of Mammeins and Surangin A”,Tetrahedron Letters,vol. 26, No. 24, pp. 2929-2932 (1985).
Ghosh, S. et al., “&agr;-Cyano-&bgr;-hydroxy-&bgr;-methyl-N-[4-(trifluoromethoxy)phenyl]Propenamide: An Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase with Potent Cytotoxic Activity against Breast Cancer Cells”,Clinical Cancer Research,vol. 4, pp. 2657-2668 (Nov. 1998).
Mahajan, S. et al., “Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFMA13 [&agr;-Cyano-&bgr;-Hydroxy-&bgr;-Methyl-N-(2,5-Dibromophenyl)Propenamide]”,Journal of Biological Chemistry,vol. 274, No. 14, pp. 9587-9599 (Apr. 2, 1999).
Rehse, K. et al., “Coumarin Derivatives Related to Calophylloid”,Arch. Pharm.,vol. 311, No. 1, pp. 52-58, Abstract only (1978).

Affiliated with

Also associated with

Rating

BTK inhibitors and methods for their identification and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BTK inhibitors and methods for their identification and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BTK inhibitors and methods for their identification and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2518435